CRP and non-small cell lung carcinoma: Of note, patients with NSCLC on atezolizumab with CRP response (OR = 5.3; χ2P < .0001) or CRP flare-response (OR = 4.4; χ2P = .0001; Figure 1, D) kinetics had an approximately fivefold increased likelihood of objective treatment response (complete or partial response) as BOR compared with CRP non-responders.